➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Baxter
Colorcon
Medtronic
Express Scripts

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation (D. Utah 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation (D. Utah 2014)

Docket   Start Trial Date Filed 2014-02-25
Court District Court, D. Utah Date Terminated 2015-03-09
Cause 35:0271 Patent Infringement Assigned To Robert James Shelby
Jury Demand Both Referred To
Parties AARP; AMBRY GENETICS; AMERICAN CIVIL LIBERTIES UNION; AMERICAN CIVIL LIBERTIES UNION FOUNDATION OF UTAH; ASSOCIATION FOR MOLECULAR PATHOLOGY; BRCA1- AND BRCA2- BASED HEREDITARY CANCER TEST PATENT LITIGATION; BREAST CANCER ACTION; COUNSYL, INC; ENDORECHERCHE; GENE BY GENE; GENEDX; HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP; INVITAE CORPORATION; LABRORATORY CORPORATION OF AMERICA HOLDINGS; MDL PANEL; MYRIAD GENETICS; PATHWAY GENOMICS; PUBLIC PATENT FOUNDATION; QUEST DIAGNOSTICS; QUEST DIAGNOSTICS NICHOLS INSTITUTE; TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; UNIVERSITY OF UTAH RESEARCH FOUNDATION
Patents 6,051,379; 6,083,698
Attorneys Adam R. Brausa; Barbara A. Jones; Benjamin G. Jackson; Brady L. Rasmussen; Brent O. Hatch; Brook B. Bond; C. Kevin Speirs; Charles L. Roberts; Colin T. Kemp; Dana E. Vallera; Daniel Greene; Daniel Ravicher; Daralyn J. Durie; David G. Mangum; David Martinez; Edgar R. Cataxinos; Elizabeth M. Flanagan; Elizabeth Mary Butler; Emmett J. McMahon; Eric W. Hagen; Geoff D. Biegler; H. Dickson Burton; Hemant K. Sabharwal; Jared J. Braithwaite; Jeremiah B. Frueauf; Jess M. Krannich; John C. Low; John M. Mejia; Jonathan E. Singer; Joseph A. Walkowski; Josephine Young; Kira A. Davis; Kirke M. Hasson; Kristine E. Johnson; Larry R. Laycock; Lenora M. Lapidus; Lesli R. Gallagher; Leslie T. Grab; Limin Zheng; Mark A. Lemley; Mark M. Bettilyon; Martin R. Lueck; Matias Ferrario; Matthew B. McFarlane; Matthew S. Gordon; MDL Panel; Mica McKinney; Michael Henry Page; Michael K. Erickson; Michael R. McCarthy; Nathan D. Thomas; Nicholas Groombridge; Nirav N. Desai; Paul D. Tripodi , II; Rebecca Fett; Rebecca L. Shult; Richard E. Mrazik; Richard L. Blaylock; Rita M. Cornish; Robert S. Clark; Sandra S. Park; Susan A. Cahoon; Tadahiro Kaburaki; Timothy Chen Saulsbury; Vanessa Lefort; William G. Gaede , III
Firms Aarp Foundation Litigation; Hatch James Dodge Pc; Jones Waldo Holbrook & McDonough (SLC); Kilpatrick Townsend & Stockton LLP; Kilpatrick Townsend & Stockton LLP(GA); McDermott Will & Emery (Ca); McDermott Will & Emery LLP; Public Patent Foundation, Cardozo School of Law; Sterne Kessler Goldstein & Fox PLLC; Wasatch-Ip
Link to Docket External link to docket
Biologic Drugs cited in In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation (D. Utah 2014)

Date Filed Document No. Description Snippet Link To Document
2014-08-07 133 LPR 2.3 Contentions Eleven Claims for U.S. Patent No. 6,051,379 and Memorandum in Support filed by MDL Notice… BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation 25 February 2014 9… 9 March 2015 2:14-md-02510 830 Patent Both District Court, D. Utah D. Utah External link to document
2014-08-13 138 LPR 2.3 Contentions Eleven Claims for U.S. Patent No. 6,051,379 in case 2:14-md-02510-RJS. Signed by Judge… BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation 25 February 2014 9… 9 March 2015 2:14-md-02510 830 Patent Both District Court, D. Utah D. Utah External link to document
2014-05-06 53 the “’109 patent”); and 6,051,379 (the “’379 patent”) (collectively, the “patents-in-suit”). Myriad further… 54. United States Patent No. 6,051,379 (the “’379 Patent”) was duly and legally issued … Myriad owns United States Patent Nos. 5,654,155; 5,750,400; 6,051,379; 6,951,721; 7,250,497; 6,083,698…United States Patent Nos. 5,709,999; 5,747,282; 5,753,441; 5,837,492; 6,033,857; 6,051,379; 6,951,721; … (Infringement of United States Patent No. 6,051,379) 53. Myriad repeats External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Mallinckrodt
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.